SG11201707473VA - Heterocyclic compounds useful as inhibitors of tnf - Google Patents
Heterocyclic compounds useful as inhibitors of tnfInfo
- Publication number
- SG11201707473VA SG11201707473VA SG11201707473VA SG11201707473VA SG11201707473VA SG 11201707473V A SG11201707473V A SG 11201707473VA SG 11201707473V A SG11201707473V A SG 11201707473VA SG 11201707473V A SG11201707473V A SG 11201707473VA SG 11201707473V A SG11201707473V A SG 11201707473VA
- Authority
- SG
- Singapore
- Prior art keywords
- tnf
- inhibitors
- heterocyclic compounds
- compounds useful
- heterocyclic
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562134800P | 2015-03-18 | 2015-03-18 | |
| PCT/US2016/022742 WO2016149439A1 (en) | 2015-03-18 | 2016-03-17 | Heterocyclic compounds useful as inhibitors of tnf |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201707473VA true SG11201707473VA (en) | 2017-10-30 |
Family
ID=55640934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201707473VA SG11201707473VA (en) | 2015-03-18 | 2016-03-17 | Heterocyclic compounds useful as inhibitors of tnf |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10112944B2 (enExample) |
| EP (1) | EP3271362B1 (enExample) |
| JP (1) | JP6779899B2 (enExample) |
| KR (1) | KR102696304B1 (enExample) |
| CN (1) | CN107567450B (enExample) |
| AU (1) | AU2016233202A1 (enExample) |
| BR (1) | BR112017019605A2 (enExample) |
| CA (1) | CA2980161A1 (enExample) |
| EA (1) | EA201792054A1 (enExample) |
| ES (1) | ES2803650T3 (enExample) |
| IL (1) | IL254430A0 (enExample) |
| MX (1) | MX2017011577A (enExample) |
| SG (1) | SG11201707473VA (enExample) |
| WO (1) | WO2016149439A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016149436A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| CA2982446A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
| EP3294726A1 (en) | 2015-04-17 | 2018-03-21 | AbbVie Inc. | Indazolones as modulators of tnf signaling |
| WO2016168641A1 (en) | 2015-04-17 | 2016-10-20 | Abbvie Inc. | Tricyclic modulators of tnf signaling |
| AR104293A1 (es) | 2015-04-17 | 2017-07-12 | Abbvie Inc | Indazolonas como moduladores de la señalización de tnf |
| GB201510758D0 (en) | 2015-06-18 | 2015-08-05 | Ucb Biopharma Sprl | Novel TNFa structure for use in therapy |
| EP3331889B1 (en) | 2015-08-03 | 2020-09-23 | Bristol-Myers Squibb Company | Cyclic compounds useful as modulators of tnf alpha |
| GB201621907D0 (en) | 2016-12-21 | 2017-02-01 | Ucb Biopharma Sprl And Sanofi | Antibody epitope |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391806A (en) * | 1982-07-12 | 1983-07-05 | The Dow Chemical Company | Substituted tetrahydropyridazino-(1,6-A)benzimidazoles and use as bronchodilators |
| AU741772B2 (en) | 1997-02-25 | 2001-12-06 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase |
| EP1479681A4 (en) | 2002-01-31 | 2006-05-10 | Daiichi Seiyaku Co | IMIDAZO (1,2-a) pyridine |
| WO2004050035A2 (en) | 2002-12-03 | 2004-06-17 | Isis Pharmaceuticals, Inc. | Benzimidazoles and analogs thereof as antivirals |
| US20050124638A1 (en) | 2003-12-08 | 2005-06-09 | Swayze Eric E. | Benzimidazoles and analogs thereof as antivirals |
| WO2008072682A1 (ja) * | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ［１，２－ｂ］ピリダジン誘導体 |
| EP2209785A1 (en) | 2007-10-05 | 2010-07-28 | S*BIO Pte Ltd | 2-morpholinylpurines as inhibitors of pi3k |
| JP2009227599A (ja) | 2008-03-21 | 2009-10-08 | Daiichi Sankyo Co Ltd | イミダゾピリダジン誘導体 |
| CN101717397B (zh) | 2008-10-09 | 2012-11-28 | 中国科学院上海药物研究所 | 一类取代吡啶并[2',1':2,3]咪唑并[4,5-c]异喹啉酮类化合物及其合成方法和用途,以及包含该类化合物的药物组合物 |
| US8691187B2 (en) | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| WO2012148550A1 (en) | 2011-02-25 | 2012-11-01 | Myrexis, Inc. | Prodrugs of therapeutic compounds |
| EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
| WO2013186229A1 (en) * | 2012-06-11 | 2013-12-19 | Ucb Pharma S.A. | Tnf -alpha modulating benzimidazoles |
| WO2014009295A1 (en) | 2012-07-13 | 2014-01-16 | Ucb Pharma S.A. | Imidazopyridine derivatives as modulators of tnf activity |
| GB201212513D0 (en) | 2012-07-13 | 2012-08-29 | Ucb Pharma Sa | Therapeutic agents |
| ES2603931T3 (es) * | 2012-11-07 | 2017-03-02 | F. Hoffmann-La Roche Ag | Compuestos de triazolo |
| WO2014080241A1 (en) * | 2012-11-21 | 2014-05-30 | Piramal Enterprises Limited | Imidazopyridine compounds and uses thereof |
| WO2015008611A1 (ja) | 2013-07-18 | 2015-01-22 | 株式会社 村田製作所 | 積層型インダクタ素子の製造方法 |
| GB201321742D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321743D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321744D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| RU2685234C1 (ru) | 2013-12-09 | 2019-04-17 | Юсб Байофарма Спрл | Конденсированные бициклические гетероароматические производные в качестве модуляторов активности tnf |
| GB201321739D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| JP6469692B2 (ja) | 2013-12-09 | 2019-02-13 | ユーシービー バイオファルマ エスピーアールエル | Ｔｎｆ活性のモジュレーターとしてのイミダゾピリジン誘導体 |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321741D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| GB201321735D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321738D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| AU2015328414B2 (en) | 2014-10-06 | 2020-03-19 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| WO2016149436A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Substituted tricyclic heterocyclic compounds |
| CA2982446A1 (en) | 2015-03-18 | 2016-09-22 | Bristol-Myers Squibb Company | Tricyclic heterocyclic compounds useful as inhibitors of tnf |
-
2016
- 2016-03-17 WO PCT/US2016/022742 patent/WO2016149439A1/en not_active Ceased
- 2016-03-17 EP EP16712647.3A patent/EP3271362B1/en active Active
- 2016-03-17 BR BR112017019605A patent/BR112017019605A2/pt not_active Application Discontinuation
- 2016-03-17 MX MX2017011577A patent/MX2017011577A/es unknown
- 2016-03-17 CA CA2980161A patent/CA2980161A1/en not_active Abandoned
- 2016-03-17 KR KR1020177029451A patent/KR102696304B1/ko active Active
- 2016-03-17 US US15/558,724 patent/US10112944B2/en active Active
- 2016-03-17 ES ES16712647T patent/ES2803650T3/es active Active
- 2016-03-17 SG SG11201707473VA patent/SG11201707473VA/en unknown
- 2016-03-17 CN CN201680026732.5A patent/CN107567450B/zh active Active
- 2016-03-17 AU AU2016233202A patent/AU2016233202A1/en not_active Abandoned
- 2016-03-17 JP JP2017548855A patent/JP6779899B2/ja active Active
- 2016-03-17 EA EA201792054A patent/EA201792054A1/ru unknown
-
2017
- 2017-09-11 IL IL254430A patent/IL254430A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3271362A1 (en) | 2018-01-24 |
| EA201792054A1 (ru) | 2018-01-31 |
| CN107567450B (zh) | 2020-03-13 |
| US10112944B2 (en) | 2018-10-30 |
| KR20170129192A (ko) | 2017-11-24 |
| IL254430A0 (en) | 2017-11-30 |
| BR112017019605A2 (pt) | 2018-05-08 |
| AU2016233202A1 (en) | 2017-11-09 |
| WO2016149439A1 (en) | 2016-09-22 |
| US20180072728A1 (en) | 2018-03-15 |
| CA2980161A1 (en) | 2016-09-22 |
| EP3271362B1 (en) | 2020-04-22 |
| CN107567450A (zh) | 2018-01-09 |
| MX2017011577A (es) | 2017-10-26 |
| ES2803650T3 (es) | 2021-01-28 |
| KR102696304B1 (ko) | 2024-08-16 |
| JP6779899B2 (ja) | 2020-11-04 |
| JP2018512062A (ja) | 2018-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2400003I1 (hu) | Kináz inhibitorként alkalmas vegyületek | |
| ME03740B (me) | Jedinjenja indol karboksamida korisna kao inhibitori kinaze | |
| ZA201800716B (en) | Heterocyclic compounds useful as modulators of tnf alpha | |
| ZA201706710B (en) | Heterocyclic compounds as lsd1 inhibitors | |
| HUE059324T2 (hu) | Heterociklusos vegyületek, mint PI3K-gamma inhibitorok | |
| IL255246A0 (en) | Heterocyclic amides as kinase inhibitors | |
| IL255817B (en) | Synthesis of heterocyclic compounds | |
| ZA201700304B (en) | Spirocycloheptanes as inhibitors of rock | |
| IL279949A (en) | Heterocyclic MCT4 inhibitors | |
| IL255750A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL254430A0 (en) | Heterocyclic compounds are useful as TNF inhibitors | |
| IL254520A0 (en) | Heterocyclic tricyclic compounds for use as tnf inhibitors | |
| GB201521059D0 (en) | Inhibitors of metallo-beta-lactamases | |
| IL247678A0 (en) | Amino-disubstituted azole compounds as tnks1 and/or tnks2 inhibitors | |
| GB201522245D0 (en) | Compounds useful as kinase inhibitors |